Will girl's death affect pending FDA decision? Print E-mail
By Jude Santos & Wire Reports   
Monday, 28 September 2009 18:39

A teenage British girl died after receiving a cervical cancer vaccine made by GlaxoSmithKline plc (NYSE:GSK), but a link between the death and the drug has not yet been established, health officials said on Monday. The 14-year-old fell ill after she was given the Cervarix vaccination against the sexually transmitted human papillomavirus (HPV) at her school in Coventry, central England, as part of a national immunization program. She later died in a hospital.

"At this stage the exact cause of this tragic death is unknown," Glaxo medical director Dr. Pim Kon said in a statement.

"As a precautionary measure, the batch of vaccine involved has been quarantined until the situation is fully understood," Kon added.

News of the death comes on the eve of a possible decision by U.S. health regulators on whether to approve Cervarix for sale in the United States. However, the U.S. Food and Drug Administration often lets its expected action dates pass without a decision, or announces a delay.

A small number of other girls at the school reported mild symptoms such as dizziness and nausea but were not admitted to a hospital, health officials said.

GlaxoSmithKline, based in Brentford, Middlesex, said more than 1.4 million doses of Cervarix had been given as part of the national immunization program.

It said adverse reactions reported so far had related to signs and symptoms of recognized side effects, or were due to the injection and not the vaccine itself.

Cervarix is administered in three separate shots over six months.

Should it gain U.S. approval it would compete with Merck & Co's Gardasil, which has been in the market in the United States since 2006 and had sales of $268 million in the second quarter. (Reporting by Michael Holden; additional reporting by Bill Berkrot in New York; Editing by Michael Roddy, Bernard Orr)

On September 9th, FDA advisers, in an 11-1 vote, said Cervarix appeared safe. Some urged monitoring of miscarriages, which were reported at a higher rate around the time of vaccination compared with a hepatitis A shot. Others urged tracking of muscle and neurological problems seen in a small number of patients.

"The data we have seen to date are reassuring, said Dr. LisaRider, a panel member and official at the National Institutes of Health. At the time she added "I think we do need very strong post-marketing studies" of autoimmune conditions that could cause neurological harm.

The committee voted 12-1 that Cervarix was effective.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter